AB-CHFUPYCA

From Wikipedia, the free encyclopedia
Jump to: navigation, search
AB-CHFUPYCA
AB-CHFUPYCA chemical structure.png
Legal status
Legal status
Identifiers
CAS Number
  • none
Chemical and physical data
Formula C22H29FN4O2
Molar mass 400.50 g/mol
3D model (Jmol)

AB-CHFUPYCA (also AB-CHMFUPPYCA)[1] is a compound that was first identified as a component of synthetic cannabis products in Japan in 2015.[2][3] The name "AB-CHFUPYCA" is an acronym of its systematic name N-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(CycloHexylmethyl)-3-(4-FlUorophenyl)-1H-PYrazole-5-CarboxAmide.

Although AB-CHFUPYCA contains structural elements common to the synthetic cannabinoid designer drugs AB-PINACA and AB-FUBINACA, it can also be considered an analog of the traditional pyrazole cannabinoid receptor 1 antagonist rimonabant. Its pharmacological properties have been the subject of only very limited study; it is presumed to be a potent agonist of the CB1 receptor.

See also[edit]

References[edit]

  1. ^ Gavin McLaughlin; Noreen Morris; Pierce V. Kavanagh; John D. Power; Brendan Twamley; John O'Brien; Brian Talbot; Geraldine Dowling; Simon D. Brandt (September 2015). "The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer". Drug Testing and Analysis. doi:10.1002/dta.1864. 
  2. ^ Uchiyama, N.; Asakawa, K.; Kikura-Hanajiri, R.; Tsutsumi, T.; Hakamatsuka, T. (August 2015). "A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide] identified in illegal products". Forensic Toxicology. 33 (2): 367–373. doi:10.1007/s11419-015-0283-8. 
  3. ^ Florian Franz; Verena Angerer; Simon D. Brandt; Gavin McLaughlin; Pierce V. Kavanagh; Bjoern Moosmann; Volker Auwärter (2016). "In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability". Drug Testing and Analysis. doi:10.1002/dta.1950.